Literature DB >> 17899289

Preoperative portal vein embolization and surgical resection in patients with hepatocellular carcinoma and small future liver remnant volume: comparison with transarterial chemoembolization.

Dong Dae Seo1, Han Chu Lee, Myoung Kuk Jang, Hyun Ju Min, Kang Mo Kim, Young Suk Lim, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh, Gi-Young Ko, Young-Joo Lee, Sung-Gyu Lee.   

Abstract

BACKGROUND: Preoperative portal vein embolization (PVE) increases the future liver remnant (FLR) volume, thus enabling surgical resection in patients with small FLR volume. It is unclear, however, if this approach can enhance survival in patients with hepatocellular carcinoma (HCC). We therefore compared the outcomes of preoperative PVE and surgical resection with transarterial chemoembolization (TACE).
METHODS: Changes in FLR volumes were analyzed in 32 HCC patients who underwent preoperative PVE and surgical resection. Long-term outcomes were compared with 64 TACE-treated patients matched for gender, Child-Turcotte-Pugh class, tumor size and number, serum alpha-fetoprotein levels, and UICC stage.
RESULTS: In the PVE group, the baseline ratio of FLR/total estimated liver volumes (TELV) was 27.6 +/- 7.2%. Following PVE, FLR volume increased 34% (336.5 vs 449.4 mL, P < .001) and the ratio of FLR/TELV increased from 27.6 +/- 7.2 to 36.9 +/- 8.1% (P < .001). There was no mortality associated with PVE or surgical resection. The 5-year survival rate was significantly higher in the PVE group than in the TACE group (71.9% vs 45.6%, P = .03). Multivariate analysis showed that treatment modality was an independent predictive factor for survival (odds ratio 2.05, 95% confidence interval 1.01-4.16, P = .046).
CONCLUSIONS: Preoperative PVE enables surgical resection in HCC patients with small FLR volume and improves patient survival compared with TACE.

Entities:  

Mesh:

Year:  2007        PMID: 17899289     DOI: 10.1245/s10434-007-9553-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  14 in total

1.  NCCN clinical practice guidelines in oncology: hepatobiliary cancers.

Authors:  Al B Benson; Thomas A Abrams; Edgar Ben-Josef; P Mark Bloomston; Jean F Botha; Bryan M Clary; Anne Covey; Steven A Curley; Michael I D'Angelica; Rene Davila; William D Ensminger; John F Gibbs; Daniel Laheru; Mokenge P Malafa; Jorge Marrero; Steven G Meranze; Sean J Mulvihill; James O Park; James A Posey; Jasgit Sachdev; Riad Salem; Elin R Sigurdson; Constantinos Sofocleous; Jean-Nicolas Vauthey; Alan P Venook; Laura Williams Goff; Yun Yen; Andrew X Zhu
Journal:  J Natl Compr Canc Netw       Date:  2009-04       Impact factor: 11.908

2.  Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma.

Authors:  Robert G Gish; Ghassan K Abou-Alfa; Myron J Tong
Journal:  Gastroenterol Hepatol (N Y)       Date:  2010-09

Review 3.  Portal vein embolization for hepatocellular carcinoma.

Authors:  Junichi Shindoh; Ching-Wei D Tzeng; Jean-Nicolas Vauthey
Journal:  Liver Cancer       Date:  2012-11       Impact factor: 11.740

Review 4.  Therapies for hepatocellular carcinoma: overview, clinical indications, and comparative outcome evaluation-part one: curative intention.

Authors:  Joseph H Yacoub; Christine C Hsu; Thomas M Fishbein; David Mauro; Andrew Moon; Aiwu R He; Mustafa R Bashir; Lauren M B Burke
Journal:  Abdom Radiol (NY)       Date:  2021-04-09

Review 5.  Role of interventional radiology in managing pediatric liver tumors : Part 2: percutaneous interventions.

Authors:  C Matthew Hawkins; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh S Thakor; Richard B Towbin; Anne Marie Cahill; Matthew P Lungren
Journal:  Pediatr Radiol       Date:  2018-02-02

6.  Efficacy of RetroNectin-activated cytokine-induced killer cell therapy in the treatment of advanced hepatocelluar carcinoma.

Authors:  Wei Li; Yaomei Wang; Daniel B Kellner; Lingdi Zhao; Linping Xu; Quanli Gao
Journal:  Oncol Lett       Date:  2016-05-25       Impact factor: 2.967

Review 7.  Strategies to increase the resectability of hepatocellular carcinoma.

Authors:  Wong Hoi She; Kenneth Sh Chok
Journal:  World J Hepatol       Date:  2015-08-28

Review 8.  Preoperative portal vein embolization for hepatocellular carcinoma: Consensus and controversy.

Authors:  Taku Aoki; Keiichi Kubota
Journal:  World J Hepatol       Date:  2016-03-28

Review 9.  Portal vein embolization and ligation for extended hepatectomy.

Authors:  Soumil Vyas; Sheraz Markar; Stefano Partelli; Tim Fotheringham; Deborah Low; Charles Imber; Massimo Malago; Hemant M Kocher
Journal:  Indian J Surg Oncol       Date:  2014-01-06

10.  Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure for hepatocellular carcinoma with chronic liver disease: a case report and review of literature.

Authors:  Michail Papamichail; Michail Pizanias; Vincent Yip; Evangellos Prassas; Andreas Prachalias; Alberto Quaglia; Praveen Peddu; Nigel Heaton; Parthi Srinivasan
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2016-05-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.